{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:25:50Z","timestamp":1793507150372,"version":"4.5.0"},"reference-count":40,"publisher":"American Association for Cancer Research (AACR)","issue":"10","funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA255074-01"],"award-info":[{"award-number":["1R01CA255074-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0282"],"award-info":[{"award-number":["W81XWH-21-1-0282"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0502"],"award-info":[{"award-number":["W81XWH-21-1-0502"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>In this phase Ib basket expansion trial and alternative-schedule dose-escalation study, we evaluated the ataxia-telangiectasia and rad3-related (ATR) inhibitor elimusertib at 40 mg twice daily (3 days on\/4 days off) in 143 patients with advanced cancer with tumor-associated DNA damage response defects, comprising gynecologic (n = 45), prostate (n = 19), colorectal (n = 24), and breast (n = 19) cancer, and ataxia-telangiectasia\u2013mutated (ATM) loss (n = 36). An alternative schedule (3 days on\/11 days off) was assessed in patients with ATM loss and\/or ATM mutations (n = 32). Elimusertib-related reversible hematologic toxicities were observed. Objective responses were modest (4.5%), but a disease control rate (DCR) of 49.3% indicated that subpopulations of patients, especially those with gynecologic cancers (DCR 59.5%), derived meaningful, durable benefits from elimusertib. There was no association between ATM protein loss or ATM alterations and progression-free survival or overall response. Further studies to define optimal predictive biomarkers for ATR inhibitors, both as monotherapy and in combination, are ongoing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This is the largest ATR inhibitor monotherapy study reported to date. A DCR of 49.3% indicated that subpopulations of patients, especially those with gynecologic cancers (DCR 59.5%), derived meaningful benefits from elimusertib. Biomarker studies suggest that early ctDNA response may potentially predict clinical benefit from ATR inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-24-1500","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T14:07:28Z","timestamp":1749910048000},"page":"2019-2035","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects"],"prefix":"10.1158","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-3309","authenticated-orcid":false,"given":"Timothy A.","family":"Yap","sequence":"first","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-5262","authenticated-orcid":false,"given":"David S.P.","family":"Tan","sequence":"additional","affiliation":[{"name":"2National University of Singapore Centre for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore."},{"name":"3Cancer Science Institute, National University of Singapore, Singapore, Singapore."},{"name":"4Department of Haematology-Oncology, National University Cancer Institute, National University Hospital, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2859-7529","authenticated-orcid":false,"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[{"name":"5Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-4095","authenticated-orcid":false,"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"6Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3863-9582","authenticated-orcid":false,"given":"Satoru","family":"Iwasa","sequence":"additional","affiliation":[{"name":"7National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-6287","authenticated-orcid":false,"given":"Markus","family":"Joerger","sequence":"additional","affiliation":[{"name":"8Kantonsspital St Gallen, St Gallen, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1192-5116","authenticated-orcid":false,"given":"Jingsong","family":"Zhang","sequence":"additional","affiliation":[{"name":"9H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0107-1444","authenticated-orcid":false,"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[{"name":"10Northern Centre for Cancer Care, Newcastle Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2640-3620","authenticated-orcid":false,"given":"Michael B.","family":"Sawyer","sequence":"additional","affiliation":[{"name":"11Cross Cancer Institute, Edmonton, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-6786","authenticated-orcid":false,"given":"Daniel S.W.","family":"Tan","sequence":"additional","affiliation":[{"name":"12National Cancer Center Singapore, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8053-4026","authenticated-orcid":false,"given":"Vincent","family":"Castonguay","sequence":"additional","affiliation":[{"name":"13Chu-de-Qu\u00e9bec Universit\u00e9 Laval, Qu\u00e9bec City, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3885-3622","authenticated-orcid":false,"given":"Nashat Y.","family":"Gabrail","sequence":"additional","affiliation":[{"name":"14Gabrail Cancer Center, Canton, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9203-4245","authenticated-orcid":false,"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[{"name":"15National Cancer Center Hospital East, Kashiwa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1949-6205","authenticated-orcid":false,"given":"Gary","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"16Bayer AG, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5035-9319","authenticated-orcid":false,"given":"Matthias","family":"Ludwig","sequence":"additional","affiliation":[{"name":"16Bayer AG, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6588-7883","authenticated-orcid":false,"given":"Andreas","family":"Schlicker","sequence":"additional","affiliation":[{"name":"16Bayer AG, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5826-6632","authenticated-orcid":false,"given":"Yinghui","family":"Zhou","sequence":"additional","affiliation":[{"name":"17Bayer HealthCare Pharmaceuticals, Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6380-0335","authenticated-orcid":false,"given":"Claudia","family":"Merz","sequence":"additional","affiliation":[{"name":"16Bayer AG, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7184-9656","authenticated-orcid":false,"given":"J. Henry M.","family":"D\u00e4britz","sequence":"additional","affiliation":[{"name":"18Bayer plc, Reading, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5239-5062","authenticated-orcid":false,"given":"Michael","family":"Jeffers","sequence":"additional","affiliation":[{"name":"19Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0383-1071","authenticated-orcid":false,"given":"Joseph","family":"Hreiki","sequence":"additional","affiliation":[{"name":"19Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-595X","authenticated-orcid":false,"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[{"name":"20The Royal Marsden Hospital, London, United Kingdom."},{"name":"21The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"2025100603072218400_bib1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","article-title":"Targeting ATR in patients with cancer","volume":"21","author":"Ngoi","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100603072218400_bib2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol Ther"},{"key":"2025100603072218400_bib3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol Cell"},{"key":"2025100603072218400_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0955-0674(00)00201-5","article-title":"DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?","volume":"13","author":"Durocher","year":"2001","journal-title":"Curr Opin Cell Biol"},{"key":"2025100603072218400_bib5","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1126\/science.1140735","article-title":"An oncogene-induced DNA damage model for cancer development","volume":"319","author":"Halazonetis","year":"2008","journal-title":"Science"},{"key":"2025100603072218400_bib6","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/cancers11091320","article-title":"Everything in moderation: lessons learned by exploiting moderate replication stress in cancer","volume":"11","author":"Nazareth","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2025100603072218400_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2025100603072218400_bib8","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.trecan.2018.09.007","article-title":"Synthetically lethal interactions of ATM, ATR, and DNA-PKcs","volume":"4","author":"Kantidze","year":"2018","journal-title":"Trends Cancer"},{"key":"2025100603072218400_bib9","doi-asserted-by":"crossref","first-page":"107450","DOI":"10.1016\/j.pharmthera.2019.107450","article-title":"Targeting ATR as cancer therapy: a new era for synthetic lethality and synergistic combinations?","volume":"207","author":"Bradbury","year":"2020","journal-title":"Pharmacol Ther"},{"key":"2025100603072218400_bib10","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","article-title":"ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer","volume":"80","author":"Rafiei","year":"2020","journal-title":"Cancer Res"},{"key":"2025100603072218400_bib11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat Chem Biol"},{"key":"2025100603072218400_bib12","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM mutations in cancer: therapeutic implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2025100603072218400_bib13","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/acs.jmedchem.0c00369","article-title":"Damage incorporated: discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in monotherapy and in combination treatments in preclinical tumor models","volume":"63","author":"L\u00fccking","year":"2020","journal-title":"J Med Chem"},{"key":"2025100603072218400_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025100603072218400_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"issue":"Suppl 1","key":"2025100603072218400_bib16","first-page":"S5","article-title":"Alternative dosing schedules for therapeutic window optimization for the ataxia telangiectasia & RAD3-related pathway (ATR) inhibitor elimusertib in patients with advanced solid tumors: M&S-based exploration using phase I data","volume":"111","author":"Zhang","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 7","key":"2025100603072218400_bib17","doi-asserted-by":"crossref","first-page":"S761","DOI":"10.1016\/j.annonc.2022.07.613","article-title":"485P Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRi) outcomes in phase I\/II clinical trials","volume":"33","author":"Ngoi","year":"2022","journal-title":"Ann Oncol"},{"key":"2025100603072218400_bib18","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1084\/jem.20121061","article-title":"Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress","volume":"209","author":"Austin","year":"2012","journal-title":"J Exp Med"},{"key":"2025100603072218400_bib19","doi-asserted-by":"crossref","first-page":"21105","DOI":"10.1073\/pnas.1111919109","article-title":"Human monocytes are severely impaired in base and DNA double-strand break repair that renders them vulnerable to oxidative stress","volume":"108","author":"Bauer","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 12","key":"2025100603072218400_bib20","doi-asserted-by":"crossref","first-page":"CT030","DOI":"10.1158\/1538-7445.AM2022-CT030","article-title":"Abstract CT030: genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-related inhibitor (ATRi), in patients (pts) with DNA damage repair (DDR) loss-of-function (LOF) mutant tumors in the Phase 1\/2 TRESR trial","volume":"82","author":"Yap","year":"2022","journal-title":"Cancer Res"},{"issue":"Suppl 7","key":"2025100603072218400_bib21","doi-asserted-by":"crossref","first-page":"S747","DOI":"10.1016\/j.annonc.2022.07.586","article-title":"457MO A phase I study of ATR inhibitor M1774 in patients with solid tumours (DDRiver Solid Tumours 301): Part A1 results","volume":"33","author":"Yap","year":"2022","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"2025100603072218400_bib22","doi-asserted-by":"crossref","first-page":"v165","DOI":"10.1093\/annonc\/mdz244.012","article-title":"450PD A phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT part A, B)","volume":"30","author":"Dillon","year":"2019","journal-title":"Ann Oncol"},{"key":"2025100603072218400_bib23","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100603072218400_bib24","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat Med"},{"key":"2025100603072218400_bib25","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","article-title":"ATR prohibits replication catastrophe by preventing global exhaustion of RPA","volume":"155","author":"Toledo","year":"2013","journal-title":"Cell"},{"key":"2025100603072218400_bib26","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.3390\/cancers13184601","article-title":"Precision oncology with drugs targeting the replication stress, ATR, and Schlafen 11","volume":"13","author":"Jo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025100603072218400_bib27","doi-asserted-by":"crossref","first-page":"10312","DOI":"10.18632\/oncotarget.14400","article-title":"Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM","volume":"8","author":"Ma","year":"2017","journal-title":"Oncotarget"},{"key":"2025100603072218400_bib28","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025100603072218400_bib29","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41571-020-0392-0","article-title":"ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper","volume":"17","author":"Dasari","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 16","key":"2025100603072218400_bib30","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1200\/JCO.2022.40.16_suppl.3082","article-title":"Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1\/2a TRESR trial (NCT04497116)","volume":"40","author":"Rosen","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 13","key":"2025100603072218400_bib31","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1158\/1538-7445.AM2019-272","article-title":"Abstract 272: synergistic activity of the ATR inhibitor BAY1895344 in combination with immune checkpoint inhibitors in preclinical tumor models","volume":"79","author":"Wengner","year":"2019","journal-title":"Cancer Res"},{"key":"2025100603072218400_bib32","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1177\/1740774510382799","article-title":"A modified toxicity probability interval method for dose-finding trials","volume":"7","author":"Ji","year":"2010","journal-title":"Clin Trials"},{"key":"2025100603072218400_bib33","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025100603072218400_bib34","unstructured":"Gynecologic Cancer InterGroup\n          . CA 125 definitions agreed by GCIG November 2005. [cited 2024 October 10]. Available from:https:\/\/gcigtrials.org\/system\/files\/CA%20125%20Definitions%20Agreed%20to%20by%20GCIG%20-%20November%202005.pdf."},{"issue":"Suppl 13","key":"2025100603072218400_bib35","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1158\/1538-7445.AM2018-5603","article-title":"Abstract 5603: analytical validation of a comprehensive 500-gene ctDNA panel designed for immuno-oncology and DNA damage research","volume":"78","author":"Helman","year":"2018","journal-title":"Cancer Res"},{"key":"2025100603072218400_bib36","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"Suppl 13","key":"2025100603072218400_bib37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/1538-7445.AM2021-401","article-title":"Abstract 401: comparison of molecular response calculations for prediction of patient outcome","volume":"81","author":"Mak","year":"2021","journal-title":"Cancer Res"},{"issue":"Suppl 5","key":"2025100603072218400_bib38","doi-asserted-by":"crossref","first-page":"PD17-02","DOI":"10.1158\/1538-7445.SABCS22-PD17-02","article-title":"Abstract PD17-02: ctDNA molecular response based on breast cancer driver mutations predicts progression in aromatase inhibitor-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2\u2212) advanced breast cancer","volume":"83","author":"Bailleux","year":"2023","journal-title":"Cancer Res"},{"key":"2025100603072218400_bib39","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"key":"2025100603072218400_bib40","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/PO.20.00321","article-title":"Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy","volume":"5","author":"Thompson","year":"2021","journal-title":"JCO Precis Oncol"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-24-1500\/3621607\/cd-24-1500.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-24-1500\/3638217\/cd-24-1500.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/15\/10\/2019\/3655797\/cd-24-1500.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/15\/10\/2019\/3655797\/cd-24-1500.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T07:07:36Z","timestamp":1759734456000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/15\/10\/2019\/765953\/Phase-Ib-Basket-Expansion-Trial-and-Alternative"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,6,16]]},"published-print":{"date-parts":[[2025,10,6]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-24-1500","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.30284338","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30284359","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30284347","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30284368","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30284356","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30284344","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30284365","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30284353","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30284341","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30284374","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30284362","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30284350","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30284371","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.8072551","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]}}}